Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 2/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisdexamfetamine SCHEMBL12947679 | 0.96 | MMP2 (0.64) | MMP2NPC1RAB9ALMNATAAR1 | |
| Lisdexamfetamine SCHEMBL25674417 | 0.96 | MMP2 (0.64) | MMP2NPC1RAB9ALMNATAAR1 | |
| Lisdexamfetamine SCHEMBL31173641 | 0.96 | MMP2 (0.64) | MMP2NPC1RAB9ALMNATAAR1 | |
| Lisdexamfetamine SCHEMBL579061 | 0.96 | MMP2 (0.64) | MMP2NPC1RAB9ALMNATAAR1 | |
| Lisdexamfetamine SCHEMBL7919487 | 0.96 | MMP2 (0.64) | MMP2NPC1RAB9ALMNATAAR1 | |
| Lisdexamfetamine SCHEMBL31439237 | 0.96 | MMP2 (0.64) | MMP2NPC1RAB9ALMNATAAR1 | |
| Lisdexamfetamine SCHEMBL158949 | 0.96 | MMP2 (0.64) | MMP2NPC1RAB9ALMNATAAR1 | |
| SCHEMBL21657924 | 0.95 | MMP2 (0.63) | MMP2NPC1RAB9ALMNATAAR1 | |
| Lisdexamfetamine SCHEMBL678421 | 0.91 | MMP2 (0.59) | MMP2NPC1RAB9ALMNATAAR1 | |
| Lisdexamfetamine SCHEMBL29124173 | 0.91 | MMP2 (0.59) | MMP2NPC1RAB9ALMNATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101571-B1 | ORNITHINE CONJUGATES OF AMPHETAMINE AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM INC (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-7776917-B2 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776917-B2 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776917-B2 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-2101571-A1 | NON-STANDARD AMINO ACID CONJUGATES OF AMPHETAMINE AND PROCESSES FOR MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090234018-A1 | Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same | SHIRE LLC | 2009-09-17 | — | — | US | disclosed |
| US-20090234018-A1 | Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same | SHIRE LLC | 2009-09-17 | — | — | US | disclosed |
| US-20090234018-A1 | Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same | SHIRE LLC | 2009-09-17 | — | — | US | disclosed |
| WO-2008073918-A1 | NON-STANDARD AMINO ACID CONJUGATES OF AMPHETAMINE AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073918-A1 | NON-STANDARD AMINO ACID CONJUGATES OF AMPHETAMINE AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080139653-A1 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080139653-A1 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080139653-A1 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC18A2, SLC6A19, SLC6A2 | MMP2 2667/4885NPC1 2023/4885RAB9A 1703/4885 |
| US-20090234018-A1 | Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same | SLC6A3, AADAT, SLC6A2 | MMP2 2552/4885NPC1 2237/4885RAB9A 1414/4885 |
| US-20080139653-A1 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | SLC6A3, AADAT, SLC6A2 | MMP2 2552/4885NPC1 2237/4885RAB9A 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.